RXII Key Stats
- RXi Pharmaceuticals (RXII) Shares to Begin Trading on OTCQX® Accesswire Jun 19
- RXI PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Of... Jun 13
- RXi Pharmaceuticals Announces Positive Results in its First Double Blind Study i... Jun 6
- RXi Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conferenc... May 20
- RXi Pharmaceuticals Reports Financial Results for the First Quarter of 2013 Marketwired May 15
- RXI PHARMACEUTICALS CORP Files SEC form 8-K, Results of Operations and Financial... May 15
- RXI PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report May 15
- VIDEO RELEASE -- Galena Biopharma Reports First Quarter 2013 Financial Results GlobeNewswire May 9
- RXi Pharmaceuticals to Present at IBC's 15th Annual TIDES: Oligonucleotide and P... May 9
- GALENA BIOPHARMA, INC. Financials Nov 17
RXII Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). RXi Pharmaceuticals is up 172.2% over the last year vs S&P 500 Total Return up 23.89%, ARCA biopharma down 57.69%, and Advanced Proteome Therpt up 146.7%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for RXII
Pro Strategies Featuring RXII
Did RXi Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.